THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Kenneth Berlin to Structure-Activity Relationship

This is a "connection" page, showing publications Kenneth Berlin has written about Structure-Activity Relationship.
  1. Synthesis and evaluation of second generation Flex-Het scaffolds against the human ovarian cancer A2780 cell line. Eur J Med Chem. 2015; 96:209-17.
    View in: PubMed
    Score: 0.119
  2. Inhibitor design to target a unique feature in the folate pocket of Staphylococcus aureus dihydrofolate reductase. Eur J Med Chem. 2020 Aug 15; 200:112412.
    View in: PubMed
    Score: 0.043
  3. Synthesis and biological evaluation of SHetA2 (NSC-721689) analogs against the ovarian cancer cell line A2780. Eur J Med Chem. 2019 May 15; 170:16-27.
    View in: PubMed
    Score: 0.039
  4. Synthesis and characterization of heteroarotinoids demonstrate structure specificity relationships. J Med Chem. 1998 Sep 10; 41(19):3753-7.
    View in: PubMed
    Score: 0.038
  5. Modified 2,4-diaminopyrimidine-based dihydrofolate reductase inhibitors as potential drug scaffolds against Bacillus anthracis. Bioorg Med Chem. 2015 Jan 01; 23(1):203-11.
    View in: PubMed
    Score: 0.029
  6. The structure and competitive substrate inhibition of dihydrofolate reductase from Enterococcus faecalis reveal restrictions to cofactor docking. Biochemistry. 2014 Feb 25; 53(7):1228-38.
    View in: PubMed
    Score: 0.028
  7. Structure-activity relationship for enantiomers of potent inhibitors of B. anthracis dihydrofolate reductase. Biochim Biophys Acta. 2013 Jan; 1834(1):46-52.
    View in: PubMed
    Score: 0.025
  8. Development of flexible-heteroarotinoids for kidney cancer. Mol Cancer Ther. 2009 May; 8(5):1227-38.
    View in: PubMed
    Score: 0.020
  9. Crystal structure of Bacillus anthracis dihydrofolate reductase with the dihydrophthalazine-based trimethoprim derivative RAB1 provides a structural explanation of potency and selectivity. Antimicrob Agents Chemother. 2009 Jul; 53(7):3065-73.
    View in: PubMed
    Score: 0.020
  10. Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. J Med Chem. 2004 Feb 12; 47(4):999-1007.
    View in: PubMed
    Score: 0.014
  11. Novel heteroarotinoids as potential antagonists of Mycobacterium bovis BCG. J Med Chem. 2004 Feb 12; 47(4):1008-17.
    View in: PubMed
    Score: 0.014
  12. Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors. J Med Chem. 1999 Oct 21; 42(21):4434-45.
    View in: PubMed
    Score: 0.010
  13. Synthesis, structure-activity relationships, and RARgamma-ligand interactions of nitrogen heteroarotinoids. J Med Chem. 1999 Sep 09; 42(18):3602-14.
    View in: PubMed
    Score: 0.010
  14. Novel heteroarotinoids: synthesis and biological activity. J Med Chem. 1991 Jan; 34(1):430-9.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES